Gracell Biotechnologies (shanghai) Co., Ltd.

Suzhou Gracell Biotechnologies Co., Ltd.

Zhongdong Shi

Jing Sun

Liping Liu

Xinxin Wang

Chunhui Yang

Wei Cao

Tao Jin

Songbai Cai

Shuyi Qiu

The present disclosure relates to an engineered immune cell and use thereof. The present disclosure provides an engineered immune cell comprising a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells of the present disclosure, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.

Compositions and methods for T cell engineering

Provided are a universal chimeric antigen receptor (CAR) T cell and preparation method and application thereof. The binding of the cell HLA-A/HLA-B to the TCR is inhibited; the TCR gene expression is silenced; the invention may be used for allogeneic tumor treatment and does not cause GVHD and HVG reaction during allogeneic infusion, and thus improves the survival and antineoplastic effect of allogeneic CAR-T cells in the recipient.

Universal chimeric antigen receptor T-cell preparation technique

Growing community of inventors

Shanghai, China

Zhongdong Shi